US Patent 8,754,123: Claim Scope, Travoprost Formulation Coverage, and Patent Landscape

US Patent 8,754,123 protects a narrow class of preservative-containing, benzalkonium-chloride-free aqueous ophthalmic solutions for lowering intraocular pressure. The core combination is a prostaglandin, preferably travoprost, Polyoxyl 40 Hydrogenated Castor Oil or a related ethoxylated/hydrogenated vegetable-oil surfactant, polyquaternium-1, and water within defined concentration ranges. The strongest commercial read-on is a BAK-free travoprost formulation corresponding closely to the Travatan Z formulation profile.

The patent is a formulation patent, not a broad travoprost compound patent. Its practical value depends on whether a competing product uses all required concentration ranges, the specified surfactant class, polyquaternium-1 or another covered polymeric quaternary ammonium compound, and the claimed preservative system.

What does US Patent 8,754,123 protect?

The independent claim requires every element below:

Claim element	Required scope
Dosage form	Aqueous ophthalmic pharmaceutical solution
Administration	Topical application to a human eye
Active ingredient	A prostaglandin suitable for lowering intraocular pressure
Prostaglandin concentration	At least 0.001% but less than 0.01% w/v
Surfactant concentration	At least 0.03% but less than 0.3% w/v
Surfactant identity	Entirely ethoxylated and/or hydrogenated vegetable oil
Single-surfactant limitation	The specified ethoxylated and/or hydrogenated castor oil is the only surfactant
Benzalkonium chloride	Composition-free of BAK
Polymeric preservative	Polymeric quaternary ammonium compound
Polymeric preservative concentration	Greater than 0.0003% but less than 0.003% w/v
Vehicle	Water

A product must satisfy the complete combination to literally infringe claim 1. Omitting the prostaglandin, using BAK, replacing the specified surfactant with a non-covered surfactant, adding a second surfactant, or moving outside a required concentration range may avoid literal infringement of claim 1. Such changes do not automatically eliminate doctrine-of-equivalents risk.

How narrow is independent claim 1?

Claim 1 is narrow in ingredient architecture but broad within that architecture.

The claim does not require travoprost. It covers any prostaglandin suitable for lowering intraocular pressure, provided the active ingredient falls within the stated concentration range. Potentially relevant prostaglandins include travoprost, latanoprost, bimatoprost, tafluprost, and related ocular hypotensive prostaglandin agents, although the commercial and technical fit will differ.

The claim also does not require polyquaternium-1 specifically. It covers a polymeric quaternary ammonium compound generally. Claim 22 narrows the scope to polyquaternium-1, and claim 23 adds the narrower concentration range from claim 20.

The most important limiting language is the surfactant requirement. The composition must contain an ethoxylated and/or hydrogenated vegetable oil as the only surfactant. A formulation containing polysorbate, poloxamer, tyloxapol, sodium lauryl sulfate, or another separate surfactant may fall outside the literal scope, depending on whether that ingredient is legally characterized as a surfactant.

What formulations are protected by the dependent claims?

The dependent claims progressively narrow the formulation toward a BAK-free, Polyoxyl 40 Hydrogenated Castor Oil-preserved travoprost product.

Claims	Added limitation
2	Surfactant below 0.15% w/v
3	Prostaglandin is travoprost
4	Prostaglandin and surfactant are nonionic
5	Surfactant is entirely ethoxylated or hydrogenated vegetable oil
6	Surfactant is entirely castor oil
7	Surfactant is entirely Polyoxyl 40 Hydrogenated Castor Oil
8	Meets Ph. Eur. A, Ph. Eur. B, or both
9	Substantially free of chloride-containing agents
10	Prostaglandin below 0.006% w/v
11	Composition is disposed in an eye dropper
20 and 21	Polymeric quaternary ammonium compound between more than 0.0007% and less than 0.0015% w/v
22	Polymeric quaternary ammonium compound is polyquaternium-1
23	Polyquaternium-1 at the narrower concentration range

Claims 16 through 19 and 23 are commercially important because they combine travoprost, low active concentration, Polyoxyl 40 Hydrogenated Castor Oil, an eye dropper, and polyquaternium-1.

Does the patent cover Travatan Z?

The claims closely track the formulation profile associated with BAK-free travoprost ophthalmic solution products.

A representative BAK-free travoprost formulation contains:

Travoprost at approximately 0.004% w/v;
Polyoxyl 40 Hydrogenated Castor Oil at approximately 0.25% w/v;
Polyquaternium-1 at approximately 0.001% w/v;
An aqueous vehicle;
No benzalkonium chloride.

Those concentrations fall within the numerical ranges in claim 1 and the narrower claims. The claimed structure also corresponds to the principal formulation distinction between conventional BAK-preserved travoprost and BAK-free travoprost preserved with polyquaternium-1.

The label and formulation must be compared against the patent claim on an ingredient-by-ingredient basis. Excipients such as boric acid, propylene glycol, mannitol, pH adjusters, and water do not necessarily avoid infringement because claim 1 does not prohibit ordinary buffers, tonicity agents, solvents, or pH-adjusting agents. The more important issue is whether an added excipient functions as a second surfactant.

When does US Patent 8,754,123 lose exclusivity?

The patent issued on June 17, 2014. Its enforceable term is generally governed by the 20-year term measured from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment and any applicable terminal disclaimer. The patent's operative expiration date should therefore be taken from the USPTO patent-term data and the prosecution history rather than calculated from the issue date.

The patent is not a drug regulatory exclusivity grant. FDA approval of a generic or 505(b)(2) product does not itself invalidate the patent. A product sponsor seeking earlier market entry would ordinarily need to address the patent through a Paragraph IV certification, a non-infringement or invalidity position, a settlement, or an entry date after patent expiration.

Patent-term implications

Issue	Business effect
Issue date	June 17, 2014
Governing term	20 years from applicable earliest nonprovisional filing date
Patent-term adjustment	May extend the ordinary term
Terminal disclaimer	Could limit the term if present in the file history
Patent-term extension	Not assumed for this formulation patent
FDA exclusivity	Separate from patent term
Generic launch	Depends on patent certifications, litigation, settlement, and regulatory approval

What is the Orange Book status of US Patent 8,754,123?

Orange Book relevance depends on whether the patent is listed for the specific approved drug product and NDA at issue. A formulation patent can be Orange Book-listed if it claims the drug, a formulation or composition of the drug, or an approved method of use under FDA listing rules.

For a BAK-free travoprost product, the relevant listing analysis should distinguish:

Patents directed to travoprost as an active compound;
Patents directed to ophthalmic compositions containing travoprost;
Patents directed to BAK-free preservation systems;
Patents directed to methods of treating glaucoma or ocular hypertension;
Patents listed for the original travoprost NDA versus a later BAK-free travoprost NDA.

The patent number alone does not establish the current Orange Book listing, delisting, or patent-use-code status. FDA Orange Book records, the product's patent listing page, and the applicable NDA must control that conclusion. The Orange Book also does not capture every potentially relevant formulation, manufacturing, or foreign patent.

How strong is the patent estate for BAK-free travoprost?

The patent is strongest against a product that copies the complete commercial architecture:

Travoprost at approximately 0.004%;
Polyoxyl 40 Hydrogenated Castor Oil as the only surfactant;
Polyquaternium-1 at approximately 0.001%;
No BAK;
Aqueous topical ophthalmic delivery;
Eye-dropper packaging.

The estate is weaker against formulations using:

A different preservative system;
No polymeric quaternary ammonium compound;
A nonionic preservative or preservative-free multidose technology;
A different solubilizer that is not an ethoxylated or hydrogenated vegetable oil;
A formulation containing a second surfactant;
Travoprost outside the claimed concentration range;
A dosage form other than the claimed aqueous solution.

Literal infringement risk matrix

Competing formulation design	Claim 1 risk
Travoprost, Polyoxyl 40 Hydrogenated Castor Oil, polyquaternium-1, BAK-free	High
Same formulation with surfactant below 0.03%	Lower literal risk
Same formulation with surfactant at 0.15%	Within claim 1; potentially within claim 2 only if below 0.15%
Same formulation with polyquaternium-1 at exactly 0.0003%	Outside the literal lower boundary
Same formulation with polyquaternium-1 at exactly 0.003%	Outside the literal upper boundary
BAK-preserved travoprost	Outside claim 1
Preservative-free travoprost	Outside the express polyquaternium-1 limitation if no polymeric quaternary ammonium compound is present
Travoprost with polysorbate as the only surfactant	Likely outside the specified surfactant class
Travoprost with Polyoxyl 40 Hydrogenated Castor Oil plus polysorbate	Potentially outside the "only surfactant" limitation
Latanoprost with the claimed excipient system	Potentially within claim 1, but not claims requiring travoprost

Numerical boundaries are material. “At least” and “greater than” include different endpoints, while “less than” excludes the stated upper endpoint. A formulation at exactly 0.0003% polyquaternium-1 would not meet the literal lower threshold in claim 1. A formulation at 0.001% would fall within claims 20, 21, and 23 if all other limitations are satisfied.

What patent landscape surrounds travoprost?

The relevant landscape has four layers.

Travoprost compound patents

Earlier Alcon patent families covered travoprost and related prostaglandin analogs. Those patents addressed the active pharmaceutical ingredient and therapeutic use rather than the specific BAK-free Polyquaternium-1 formulation. Their expiration dates and Orange Book status are separate from US 8,754,123.

Formulation patents

US 8,754,123 is directed to the combination of:

Low-dose prostaglandin;
Ethoxylated or hydrogenated vegetable-oil surfactant;
Polymeric quaternary ammonium preservative;
Absence of BAK.

This is the principal formulation layer relevant to BAK-free travoprost products.

Method-of-use patents

A separate method-of-use patent may cover treating glaucoma, ocular hypertension, or reducing intraocular pressure with travoprost. Such claims can create a separate Paragraph IV issue even when a generic applicant designs around the formulation claims.

Manufacturing and process rights

Manufacturing patents may cover solubilization, mixing order, sterilization, container filling, low-volume ophthalmic packaging, or stability control. Those rights may not appear in the Orange Book. A product can avoid a formulation patent yet still encounter process or trade-secret barriers, particularly where the formulation requires tight control of solubilization and preservative concentration.

Which companies are likely to challenge the patent?

Generic ophthalmic manufacturers and specialty pharmaceutical companies are the principal potential challengers. Relevant market participants historically include companies such as Sandoz, Apotex, Dr. Reddy's Laboratories, Teva, Viatris, and other firms active in generic ophthalmic products.

A challenge could proceed through:

An ANDA with a Paragraph IV certification;
A section viii statement carving out a patented method of use;
A 505(b)(2) application;
A declaratory-judgment action;
A commercial launch followed by patent litigation.

The specific challenger, filing date, asserted claims, court, and settlement terms must be determined from the ANDA litigation docket and FDA regulatory records. A generic approval does not prove that the generic product practices the patent. Conversely, a formulation change in the approved label does not eliminate potential process or doctrine-of-equivalents claims.

What Paragraph IV risks exist?

A Paragraph IV challenge would likely focus on three areas.

Non-infringement

The applicant may argue that its formulation:

Uses a different surfactant;
Contains no surfactant;
Uses a different preservative;
Falls outside the numerical concentration ranges;
Contains BAK or another preservation system;
Uses a different dosage form or delivery system.

The “only surfactant” limitation is a potentially important design-around point. The applicant would need analytical and regulatory support for its characterization of each excipient.

Invalidity

Potential invalidity arguments could address:

Anticipation by earlier ophthalmic compositions;
Obviousness based on known prostaglandin formulations, castor-oil surfactants, and polyquaternium preservatives;
Written-description or enablement issues concerning the breadth of “a prostaglandin” and “a polymeric quaternary ammonium compound”;
Indefiniteness in the “entirely ethoxylated and/or hydrogenated vegetable oil” language;
Indefiniteness or scope disputes concerning “substantially free” and “suitable for lowering intraocular pressure.”

The patent's dependent claims reduce some validity risk by identifying travoprost, Polyoxyl 40 Hydrogenated Castor Oil, polyquaternium-1, and specific concentration windows.

Settlement and launch timing

A settlement could provide an authorized-generic arrangement, a licensed launch date, or a supply agreement. The principal commercial value is the gap between regulatory approval and permitted market entry. A settlement's treatment of BAK-free formulation claims, authorized generic rights, and future formulation changes would materially affect valuation.

Does the patent cover biosimilars?

No. Travoprost is a chemically synthesized small-molecule prostaglandin, not a biologic. Biosimilar approval under the Public Health Service Act is therefore not the relevant pathway.

Potential competitors would ordinarily pursue an ANDA for a pharmaceutically equivalent ophthalmic solution or, in some circumstances, a 505(b)(2) application. The main regulatory and patent issues are therapeutic equivalence, inactive-ingredient safety, sterility, container closure, preservative performance, and patent certifications.

What is the geographic coverage?

US Patent 8,754,123 provides rights only in the United States. Related PCT, European, Canadian, Japanese, or other national applications may have different claims, prosecution outcomes, expiration dates, and enforceability.

A global launch assessment should separate:

US composition claims;
European formulation claims;
Canadian and Australian equivalents;
Manufacturing-country patents;
Regulatory exclusivity in each market;
Patent-term extensions or supplementary protection certificates.

A foreign product can be manufactured outside the United States without avoiding US infringement if the product is imported, sold, or offered for sale in the United States.

Key Takeaways

US 8,754,123 is a narrow but commercially relevant formulation patent.
Its core scope covers a BAK-free aqueous prostaglandin ophthalmic solution with an ethoxylated or hydrogenated vegetable-oil surfactant, polyquaternium-type preservative, and defined concentration ranges.
Travoprost, Polyoxyl 40 Hydrogenated Castor Oil, and polyquaternium-1 are expressly covered by dependent claims.
A formulation matching approximately 0.004% travoprost, 0.25% Polyoxyl 40 Hydrogenated Castor Oil, and 0.001% polyquaternium-1 presents the highest literal infringement risk.
BAK-containing, preservative-free, non-castor-oil, or multi-surfactant formulations may offer design-around positions.
The patent is separate from earlier travoprost compound patents and from any method-of-use or manufacturing patents.
Orange Book status, patent-term adjustment, terminal disclaimers, Paragraph IV litigation, and settlement terms must be confirmed from FDA, USPTO, and court records before a launch or licensing decision.

FAQs About US Patent 8,754,123

Is Polyquaternium-1 the same as Polyquad?

Yes. Polyquad is a commercial name commonly associated with polyquaternium-1, the polymeric quaternary ammonium compound expressly identified in claims 22 and 23.

Does adding benzalkonium chloride avoid US Patent 8,754,123?

It likely avoids the express BAK-free limitation in claim 1, but it may create other regulatory, safety, formulation, or patent issues. It does not resolve potential infringement of unrelated patents.

Is a travoprost concentration of exactly 0.006% covered?

Claim 10 requires a concentration below 0.006% and therefore does not literally cover exactly 0.006%. Claim 1 remains potentially relevant because it covers concentrations below 0.01%, provided every other limitation is met.

Can a generic use a different castor-oil surfactant?

Possibly. The answer depends on whether the substitute is an ethoxylated or hydrogenated vegetable oil within the claim language and whether it is the only surfactant. Claims 6 and 7 narrow the patent to castor oil and Polyoxyl 40 Hydrogenated Castor Oil, respectively.

Does an eye-dropper limitation apply to every claim?

No. Claim 11 and the claims depending from it require the composition to be disposed in an eye dropper. Claim 1 does not require an eye-dropper container, so a non-dropper package may still fall within claim 1 if the composition limitations are satisfied.

References

United States Patent No. 8,754,123, Ophthalmic compositions containing a prostaglandin and a polymeric quaternary ammonium compound, issued June 17, 2014.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/
U.S. Food and Drug Administration. (n.d.). Travoprost ophthalmic solution prescribing information. FDA-approved product labeling.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No	8,754,123	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070888	⤷ Start Trial
Argentina	124058	⤷ Start Trial
Australia	2009225824	⤷ Start Trial
Brazil	PI0908717	⤷ Start Trial
Canada	2716994	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,754,123

Which drugs does patent 8,754,123 protect, and when does it expire?

Summary for Patent: 8,754,123